Navigation Links
CoAxia, Inc. Announces $21.5M Series D Financing
Date:6/22/2009

nt, we are pleased to have raised a sizeable, and oversubscribed, financing round. These funds will provide the resources to finalize our pivotal trial and demonstrate safety and efficacy. Looking forward, with Sofinnova's experience in financing medical device companies developing breakthrough technologies to successful exits, we believe that we are now well positioned for trial completion, PMA submission and initiation of sales and marketing."

Antoine Papiernik, Managing Partner at Sofinnova Partners commented: "Sofinnova is pleased to have led the Series D round for CoAxia. We have long been interested in treatment opportunities in ischemic stroke, given the very large, global, untreated population. We had been following CoAxia's progress for many years and we felt it was the right time to get involved. We find the NeuroFlo technique very compelling, given its ease of use, excellent safety profile and impressive early clinical results. If the SENTIS trial is successful, we believe that NeuroFlo has the potential to become a standard of care. We are very impressed with the strength of CoAxia's operating team, and are convinced that they can continue to deliver on the NeuroFlo potential. I look forward to joining CoAxia's Board of Directors for this exciting period ahead."

CoAxia, Inc. is a venture-backed, privately held, clinical-stage company providing perfusion augmentation therapies to improve outcomes for patients with cerebral ischemia resulting from stroke, vasospasm and other conditions. In addition to the SENTIS, Flo24 and FASTFlo trials for ischemic stroke, CoAxia's NeuroFlo(TM) & FloControl(TM) devices have been approved by the US FDA via Humanitarian Device Exemption for the treatment of cerebral vasospasm, have received US FDA 510(k) clearance, and have secured the CE Mark for cerebral perfusion augmentation.

Sofinnova Partners is an independent venture capital firm based in Paris, France that spec
'/>"/>

SOURCE CoAxia, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
2. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
3. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
4. ThermoGenesis Announces National Institute of Health Grant
5. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
6. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
7. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
10. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
11. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Research and Markets has announced ... Markets" report to their offering. ... - including products to treat cancer, diabetes, HIV/AIDS and ... the final stages of clinical drug testing for new ... production capital to upscale while anticipating FDA or EMA ...
(Date:9/23/2014)... Canada , September 23, 2014 ... and lifestyle related disorders and increasing number of foreign ... demand for probiotic in India ... as one of the most high growth potential markets ... concerns among consumers especially among the youth, changing food ...
(Date:9/23/2014)... Sept. 23, 2014  SiteOne Therapeutics Inc. today announced ... Led by Sears Capital Management and Biobrit LLC, with ... , the $1.5 million financing positions SiteOne to advance ... and to further develop its technology platform for long-acting ... In conjunction with the financing, Lowell Sears ...
Breaking Medicine Technology:Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3
... announces that a new market research report is available ... http://www.reportlinker.com/p0357031/Regenerative-Medicine-Markets.html Regenerative ... human tissue by using laboratory-grown or therapeutically-induced human tissue ... the ability to repair or replace damaged human tissue ...
... YORK, Dec. 29, 2010 Reportlinker.com announces that ... its catalogue: 2010-2015 In-depth Research ... http://www.reportlinker.com/p0356862/2010-2015-In-depth-Research-Report-on-China-Sodium-Fluoride-Industry.html Report ... State Statistical Bureau, General Administration of Custom, Ministry ...
Cached Medicine Technology:Reportlinker Adds Regenerative Medicine Markets 2Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry 2
(Date:9/23/2014)... The inaugural single day event in Japan will ... Gardens in Tokyo. Clinical data scientists will meet and discuss ... second single day event in China will be ... clinical data scientists attending this event will discuss topics around ... display data collected in clinical studies and beyond. , ...
(Date:9/23/2014)... COLUMBIA, Mo. Infants, vocalizations throughout the first ... crying and cooing to forming syllables and first ... the amount of vocalizations may differ between hearing ... shows that infant vocalizations are primarily motivated by ... infants with profound hearing loss who received cochlear ...
(Date:9/23/2014)... of published studies found that FDG-PET technology is ... disease in regions where infections like histoplasmosis or ... suspicious for cancer could lead to unnecessary tests ... and mortality. , Histoplasmosis and other fungal ... concentrated in bird droppings and are found in ...
(Date:9/23/2014)... World of Home Fitness is committed ... recently, the gym has been raising money to support ... the year, World of Home Fitness has participated in ... Over the summer, World of Home Fitness raised more ... Fitness program, participants helped feed seniors "one rep at ...
(Date:9/23/2014)... As a consumer in today’s world, ... It’s difficult to trust testimonials that are supplied by ... manipulate their customers into saying anything. , Consumer advocacy ... to lack in depth coverage on a particular market ... to fix this issue and focus on exposing the ...
Breaking Medicine News(10 mins):Health News:PhUSE Further Expands its Global Community Into the Asian Region 2Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Consumer Health Reports Debuts Revolutionary Review Website 2
... for, immunization against diphtheria, tetanus, pertussis, polio and Haemophilus ... ... LYON, France, June 23 Sanofi,Pasteur, the vaccines division of ... Administration (FDA) has licensed Pentacel(R),Diphtheria and Tetanus Toxoids and Acellular ...
... of persistent, recent-onset symptoms linked to ovarian cancer ... quickly and abdominal bloating when combined with the ... ovarian cancer by 20 percent, according to new findings ... online today in CANCER . , Research has ...
... Delivery Unit at The Children,s,Hospital of Philadelphia, the ... birth defects, PHILADELPHIA, June 22 Hundreds ... Hospital of Philadelphia for,the 12th Annual Fetal Surgery ... been followed by the Center for Fetal Diagnosis ...
... are struggling with the health fallout caused by a lack ... Most women don,t need a survey to tell them a ... too sluggish to make it through the day with vigor. ... moms, empty-nesters or grandmothers, many -- if not most -- ...
... best in those under 80, could ease expected worldwide shortfall ... blood substitute product called HBOC-201 proved safe and effective in ... reports. , In all, 688 patients, ages 18 and ... unit of blood (about one pint) or an equivalent one ...
... India, June 20 The United States,has provided ... the Children to assist people affected by the ... Shortages have emerged in recent months because the ... rapidly growing rat infestations in,crop-growing areas. With funds ...
Cached Medicine News:Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 5Health News:Symptom screening plus a simple blood test improves early detection of ovarian cancer 2Health News:12th Annual Fetal Surgery Family Reunion Gathers Families From Across the U.S. and Canada 2Health News:12th Annual Fetal Surgery Family Reunion Gathers Families From Across the U.S. and Canada 3Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Blood Substitute Found Safe in Large Phase III Trial 2
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. The procedure can be done in the office under topical anesthesia. Complete Set Includes Vacuum Speculum, ...
... Streamline family of temporary sensing and pacing ... standard in temporary pacing leads and improved ... to use and less traumatic to heart ... are designed to provide consistent temporary sensing ...
Carbo-Seal Valsalva AAP is the first valved graft to replicate the natural Sinus of Valsalva, encouraging the natural formation of systolic vortices....
Current annuloplasty rings and bands are designed for symmetric dilatation. The IMR ETlogix ring is the first asymmetric ring designed to treat asymmetric dilatation....
Medicine Products: